Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Scientists have made a remarkable breakthrough in kidney research. In a paper published in the journal Communications Biology, a team of researchers at Kyoto University led by Ramin Sadeghian present ...

Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...

A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.

ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...